Precautionary principle

The precautionary principle holds that where an activity threatens serious or irreversible harm, the absence of scientific certainty about that harm is not a sufficient reason to allow the activity to proceed unrestricted. It exists in weak versions that merely license regulators to act under uncertainty and strong versions that shift the burden of proof onto whoever proposes the activity. The difference between those versions is not a matter of degree, and most arguments about the principle are really arguments about which one is being invoked.

§Formulations

The weak form authorises action; the strong form requires it. A third and stronger reading, sometimes attributed to the principle by its critics and rarely defended in print, would prohibit any activity whose safety cannot be affirmatively demonstrated. That reading is genuinely incoherent, since no activity can be shown safe in that sense and inaction has consequences of its own — but it is a straw man of the versions that appear in law.

§Origins and legal status

The German Vorsorgeprinzip — roughly, the principle of taking care in advance — entered environmental legislation in the 1970s as a rationale for acting on forest damage and air pollution before causal chains were established. The idea spread through North Sea protection conferences in the 1980s and reached its most-quoted formulation as Principle 15 of the 1992 Rio Declaration.

In European Union law the principle has treaty status as one of the bases of environmental policy, and a European Commission communication in 2000 set out how it should be applied: measures must be proportionate, non-discriminatory, consistent with comparable measures elsewhere, based on an examination of costs and benefits, and subject to review as evidence accumulates.¹ That document is the most operationally careful statement of the doctrine in existence, and it is considerably more restrained than the principle's reputation suggests.

The Cartagena Protocol on Biosafety, adopted in 2000, is the main instrument applying precaution to biotechnology specifically, permitting parties to restrict imports of living modified organisms where scientific information is insufficient. UNESCO's world commission on the ethics of scientific knowledge issued a report in 2005 attempting a general definition and application framework.

§How it operates in biotechnology

The principle's record in this field is genuinely mixed, and both camps cite it selectively.

Where precaution has been vindicated. The 1975 Asilomar Conference on Recombinant DNA is the field's founding case: researchers imposed a moratorium on recombinant DNA work under acknowledged uncertainty, developed containment levels, and resumed. The moratorium lasted under a year and produced a containment framework that is still the template for self-governance in the field. The requirement that drug sponsors demonstrate safety and efficacy before marketing — a burden-shifting rule of exactly the strong-form type — is uncontroversial and followed a series of harms including thalidomide.

Where precaution has been costly. The European Union's de facto moratorium on approvals of genetically modified crops from 1999 was found by a World Trade Organization panel in 2006 to have caused undue delay. A 2018 Court of Justice ruling brought organisms produced by genome editing within the EU's GMO directive, subjecting edits indistinguishable from natural mutations to the full approval regime; the Commission subsequently proposed a separate regime for new genomic techniques. In 2024 a Philippine appellate court revoked biosafety permits for Golden Rice and Bt eggplant on precautionary grounds, a decision that was appealed. In each case, the costs of delay fell on people who would have benefited and are not counted in the risk assessment.

Where the argument is live. Gene drives releases are the clearest current test, because a self-propagating edit cannot be recalled and field trials are the only way to obtain the missing information. Proposals for Human germline editing are governed by an explicitly precautionary international consensus, discussed in Governance of human genome editing, which the He Jiankui affair hardened rather than created. The 2024 call by a large group of scientists to halt work toward Mirror life is a precautionary argument in its purest modern form: the authors argue that chirally inverted organisms could evade immune recognition across many species, that no adequate defence is known, and that the research should stop before the capability exists.²

Why the biotechnology cases differ

Most environmental applications of the principle concern harms that are gradual and in principle reversible. The cases that dominate this wiki — self-spreading edits, heritable modification, novel replicators — involve irreversibility as a structural feature. That is the condition under which even the principle's critics tend to concede it has force.

§Criticisms

The central objection, argued at length by Cass Sunstein, is that the principle is incoherent as a decision rule because it forbids the very steps it requires.³ Regulation has risks; so does non-regulation. Banning a pesticide risks crop loss; approving it risks toxicity. If the principle counsels avoiding uncertain serious harm, it counsels both action and inaction simultaneously, and it appears to give determinate guidance only because attention has been selectively directed at one side of the ledger. Sunstein attributes this selectivity to known features of risk perception: availability, loss aversion, and greater aversion to harms caused by human action than to statistically larger harms caused by omission.

A second objection concerns risk–risk tradeoffs: interventions displace risk rather than removing it, and the displaced risk is systematically undercounted because it lands on different people at a later time.

A third objection is that the principle has no stopping rule. Since certainty is unavailable in principle, any threshold for "sufficient evidence" is a judgement imported from outside the principle, which means the principle is not doing the work its invocation implies.

A fourth is that it is applied asymmetrically to novel technologies. Existing practices with well-characterised large harms are grandfathered, while novel practices with speculative small harms face the burden — a pattern visible in the regulatory treatment of Xenotransplantation relative to the ongoing mortality documented in Organ shortage.

§The proactionary reply

Max More proposed the proactionary principle in 2004 as an explicit counterweight, articulating a presumption in favour of proceeding: freedom to innovate is valuable, restriction has costs that must be counted symmetrically, and evaluation should use the best available evidence rather than worst cases, weighting probability rather than mere possibility.⁴ The formulation has roots in Extropianism and has been developed at book length by Steve Fuller and Veronika Lipinska.

Its weakness mirrors the precautionary principle's. Stated weakly it is a plea for symmetric accounting, which almost everyone accepts. Stated strongly it presumes in favour of action under uncertainty, which is as arbitrary as presuming against. The strand of Effective accelerationism that treats technological advance as intrinsically good takes the strong reading, generally without the accounting.

§Asymmetric-risk versions

The most defensible modern formulations abandon the attempt at a general rule and specify the conditions under which precaution is rational. Nassim Taleb and colleagues argue that precaution is warranted where potential harm is systemic and ruinous — where the affected system is coupled enough that damage propagates and the downside includes irreversible collapse — and unwarranted for risks that are local and bounded, however alarming.⁵ On their analysis, an activity with a small chance of unbounded harm repeated indefinitely has a probability of ruin approaching one, which is an argument from the structure of the payoff rather than from uncertainty as such.

Sunstein himself endorses a narrower "anti-catastrophe" version on similar grounds: where a harm is potentially irreversible and catastrophic, and the option to wait has value, paying to preserve future flexibility can be justified even under deep uncertainty. Nick Bostrom's work on Existential risk arrives at the same structure from a different direction, and Differential technological development can be read as an attempt to convert that structure into a policy that sequences technologies rather than blocking them.

§Outlook

The principle's practical future in biotechnology depends on a question it cannot answer internally: who counts the costs of delay. Approval regimes make the risks of action visible and attributable, while the harms of inaction — untreated disease, forgone yield, deaths on transplant waiting lists — are diffuse and statistical. Proposals to fix the asymmetry range from mandatory counting of forgone benefits in regulatory impact assessment to conditional approval with mandatory post-market surveillance, the model already used for accelerated drug approvals. None has been adopted broadly enough to test whether it changes outcomes, and the technologies now arriving in Synthetic genomes and self-propagating systems are precisely the ones where getting the accounting wrong in either direction is expensive.

§See also

• Bioconservatism
• Differential technological development
• Existential risk
• Dual-use research of concern
• Governance of human genome editing
• Mirror life
• Max More
• Asilomar Conference on Recombinant DNA

§References